Immunic, Inc. Common Stock
IMUXStock
$15.03+81.27%52W
Market Cap$204.73M
P/E—
Div yield—
Beta1.39
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)109.38%
Price vs S&P 500 (4W)9.54%
VGM Score81.07
Market Capitalization$204.73M
Earnings Surprise History
Q1 26-1.08est. -0.93
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.27
4.33
4.36
4.38
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IMUXImmunic, Inc. Common Stock | — | — | A | $15.03 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Immunic is a clinical-stage biopharmaceutical company developing selective oral therapies for chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. The company's pipeline includes three lead candidates: IMU-838 (immune cell metabolism inhibitor), IMU-935 (RORγt pathway modulator), and IMU-856 (intestinal barrier restoration). These therapies target large patient populations with significant unmet treatment needs.